重性抑郁障碍患者肠道菌群特征与SSRIs类抗抑郁药疗效的关联分析

doi:10.20223/j.cnki.1000-8535.2026.02.016

摘要/Abstract

摘要： 目的探讨重性抑郁障碍（MDD）患者肠道菌群特征与选择性5-羟色胺再摄取抑制剂（SSRIs）疗效的关联性,筛选可预测SSRIs疗效的肠道菌群生物标志物。方法选取2024年5月—2025年5月宁夏回族自治区人民医院收治的90例MDD患者,根据SSRIs治疗8周后疗效分为应答组56例和无应答组34例,并选择30例健康对照,采集基线粪便样本进行16S rRNA基因测序,分析肠道菌群α多样性、菌属相对丰度差异,并通过相关性分析、多因素Logistic回归及ROC曲线评估菌群标志物对SSRIs疗效的预测价值。结果 MDD患者肠道菌群Chao1指数、Shannon指数低于健康对照（P<0.05）,应答组与无应答组α多样性无差异（P>0.05）。应答组基线Blautia、双歧杆菌属、粪球菌属丰度高于无应答组（P<0.05）,大肠杆菌-志贺菌属丰度低于无应答组（P<0.05）。基线Blautia、双歧杆菌属、粪球菌属丰度与SSRIs治疗8周HAMD-17减分率呈正相关（r分别为0.390、0.420、0.350,均P<0.05）,三者联合预测SSRIs疗效的ROC曲线下面积（AUC）为0.910（灵敏度83.9%,特异度85.3%）。结论 MDD患者存在肠道菌群结构异常,基线Blautia、双歧杆菌属、粪球菌属丰度可作为SSRIs疗效的潜在预测标志物,为MDD个体化治疗提供实验依据。

关键词: 重性抑郁障碍, 肠道菌群, 选择性5-羟色胺再摄取抑制剂, 疗效预测, 生物标志物, 16S rRNA基因测序

Abstract: Objective To explore the association between gut microbiota characteristics and the efficacy of selective serotonin reuptake inhibitors（SSRIs）in patients with major depressive disorder（MDD）,and to screen gut microbiota biomarkers for predicting SSRIs efficacy．Methods A total of 90 MDD patients（divided into responders[n=56] and non-responders[n=34] based on 8-week SSRIs efficacy）and 30 healthy controls were enrolled from May 2024 to May 2025．Fecal samples were collected for 16S rRNA gene sequencing to analyze gut microbiota α diversity and genus-level relative abundance．Correlation analysis,multivariate logistic regression,and receiver operating characteristic curve were used to evaluate the predictive value of microbiota markers for SSRIs efficacy．Results The Chao1 and Shannon indices of gut microbiota in MDD patients were significantly lower than those in healthy controls（P<0.05）,with no difference between responders and non-responders（P>0.05）．Responders had higher baseline abundances of Blautia,Bifidobacterium,and Coprococcus（P<0.05）,and lower abundance of Escherichia-Shigella compared to non-responders．Baseline abundances of Blautia,Bifidobacterium（P<0.05）,and Coprococcus were positively correlated with 8-week HAMD-17 reduction rate（r=0.390,0.420,0.350;all P<0.05）．The combined prediction of these three genera for SSRIs efficacy showed an area under the curve of 0.910（sensitivity 83.9%,specificity 85.3%）．Conclusions MDD patients exhibit abnormal gut microbiota structure．Baseline abundances of Blautia,Bifidobacterium,and Coprococcus may serve as potential predictive biomarkers for SSRIs efficacy,providing experimental basis for personalized treatment of MDD．

Key words: major depressive disorder, gut microbiota, selective serotonin reuptake inhibitors, efficacy prediction, biomarker, 16S rRNA gene sequencing

李媛媛, 兰小梅, 刘亚贤, 丁红英. 重性抑郁障碍患者肠道菌群特征与SSRIs类抗抑郁药疗效的关联分析[J]. 广州医药, 2026, 57(2): 233-239.

LI Yuanyuan, LAN Xiaomei, LIU Yaxian, DING Hongying. Analysis of the association between gut microbiota characteristics and efficacy of SSRIs antidepressants in patients with major depressive disorder[J]. Guangzhou Medical Journal, 2026, 57(2): 233-239.

参考文献

[1] 刘晓燕,谭美玉,郭洋达,等.氟哌噻吨美利曲辛联合帕罗西汀对重度抑郁障碍患者躯体化症状、睡眠和认知功能的影响分析[J].广州医药,2024,55(7):747-751.
[2] 李伟,杜若南,蔡海鹏,等.电休克疗法对伴有自杀意念重性抑郁障碍青少年的疗效与安全性研究[J].中国神经精神疾病杂志,2025,51(3):142-148.
[3] 李冕,谭忠林,吴月,等.重性抑郁障碍谷氨酸与γ-氨基丁酸稳态失衡研究进展[J].中国神经精神疾病杂志,2023,49(12):758-764.
[4] 胡晓东,席燕晴,王宗琦,等.5-羟色胺选择性再摄取抑制剂抗抑郁药物对首发抑郁障碍病人认知功能的影响[J].中西医结合心脑血管病杂志,2022,20(21):4019-4021.
[5] 谢福,唐干,杨楠,等.帕金森病伴抑郁患者肠道菌群特征及其与心理因素相关性研究[J].中国神经精神疾病杂志,2025,51(5):274-279.
[6] 邵晶,陈红霞,吕书勤.基于“微生物-肠道-脑轴” 理论探讨中药防治阿尔茨海默病的研究进展[J].中国医药科学,2024,14(7):46-50.
[7] 吴依凡,杜东霖,孙晓川.微生物-肠道-脑轴在神经系统疾病中的研究进展[J].重庆医学,2022,51(1):143-146,153.
[8] 徐云帆,刘鹏鸿,郭峰涛,等.伴应激事件抑郁障碍患者肠道菌群特征及相关性研究[J].中国微生态学杂志,2025,37(3):294-303.
[9] 马英英,李秀梅,雷津平,等.重性抑郁障碍患者肠道菌群特征与艾司西酞普兰治疗效果的关联分析[J].临床精神医学杂志,2025,35(1):6-10.
[10] ORTEGA M A,ALVAREZ-MON M A,GARCÍA-MONTERO C,et al.Gut microbiota metabolites in major depressive disorder-deep insights into their pathophysiological role and potential translational applications[J].Metabolites,2022,12(1):50.
[11] BRUUN C F,HALDOR HANSEN T,VINBERG M,et al.Associations between short-chain fatty acid levels and mood disorder symptoms:A systematic review[J].Nutr Neurosci,2024,27(8):899-912.
[12] 王茜,张莉,佟洋,等.复合益生菌对老年重度抑郁症患者的疗效[J].中国微生态学杂志,2025,37(3):323-330.
[13] 卢瑾,李凌江,许秀峰.中国抑郁障碍防治指南(第二版)解读:评估与诊断[J].中华精神科杂志,2017,50(3):169-171.
[14] ALLI S R,GORBOVSKAYA I,LIU J C W,et al.The gut microbiome in depression and potential benefit of prebiotics,probiotics and synbiotics:A systematic review of clinical trials and observational studies[J].Int J Mol Sci,2022,23(9):4494.
[15] GAO M,WANG J,LIU P,et al.Gut microbiota composition in depressive disorder:A systematic review,meta-analysis,and meta-regression[J].Transl Psychiatry,2023,13(1):379.
[16] JIANG Y,QU Y,SHI L,et al.The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder[J].Transl Psychiatry,2024,14(1):493.
[17] CHEN L,WANG D,GARMAEVA S,et al.The long-term genetic stability and individual specificity of the human gut microbiome[J].Cell,2021,184(9):2302-2315.e12.
[18] NIU Y,HU X,SONG Y,et al.Blautia coccoides is a newly identified bacterium increased by leucine deprivation and has a novel function in improving metabolic disorders[J].Adv Sci,2024,11(18):e2309255.
[19] WANG M,FENG X,ZHAO Y,et al.Indole-3-acetamide from gut microbiota activated hepatic AhR and mediated the remission effect of Lactiplantibacillus plantarum P101 on alcoholic liver injury in mice[J].Food Funct,2023,14(23):10535-10548.
[20] LIN S,LI Q,XU Z,et al.Detection of the role of intestinal flora and tryptophan metabolism involved in antidepressant-like actions of crocetin based on a multi-omics approach[J].Psychopharmacology,2022,239(11):3657-3677.
[21] HÉMA A,SERMÉ S S,SAWADOGO J,et al.Contribution of the rapid LAMP-based diagnostic test(RLDT)to the evaluation of enterotoxigenic Escherichia coli(ETEC)and Shigella in childhood diarrhea in the peri-urban area of Ouagadougou,Burkina Faso[J].Microorganisms,2023,11(11):2809.
[22] CHEN X,SHI S,SUN C,et al.A study of the relationship between inflammatory immune function and intestinal flora in adolescent patients with first-episode depression[J].Actas Esp Psiquiatr,2024,52(1):1-9.
[23] OU J,ELIZALDE P,GUO H B,et al.TCA and SSRI antidepressants exert selection pressure for efflux-dependent antibiotic resistance mechanisms in Escherichia coli[J].mBio,2022,13(6):e0219122.
[24] WANG Y,ZHOU J,YE J,et al.Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder[J].Microbiome,2023,11(1):195.
[25] ZENG J W,ZHAO J L,HAN Z J,et al.Narrative review:pathogenesis of the inflammatory response and intestinal flora in depression[J].Neuropsychiatr Dis Treat,2023(19):2469-2483.